July 17, 2026

House China Deadline Arrives, LIPFENDRA Analyst Reaction, FDA Grants Fabhalta Traditional Approval

House China Committee July 17 deadline arrives today; Merck LIPFENDRA analyst coverage; Novartis Fabhalta traditional approval in IgAN; PCAC 6 days out.

4 stories · Covering regulatory, industry

Editor's Note

Friday's digest sits at two procedural cutoffs. The House Select Committee on the Chinese Communist Party's July 17 response deadline arrives today for five drugmakers whose Xinjiang-region and Chinese military-medical-center clinical-trial records were requested June 29: Merck (224 China studies since 2005, 31 Xinjiang plus 40 military), Eli Lilly (220-plus studies since 2003, 11 Xinjiang plus 16 military), Pfizer (6 Xinjiang plus 43 military), AbbVie (100-plus studies, 17 Xinjiang plus 16 military), and Bristol-Myers Squibb (180 China studies since 2004, 8 Xinjiang plus 17 military 2015-2024). One week from tomorrow, the FDA Pharmacy Compounding Advisory Committee (PCAC) opens the July 23-24 meeting on seven peptides, with docket FDA-2025-N-6895 closing at 11:59 PM ET Wednesday July 22. On the peptide-approval side, analyst coverage of yesterday's Merck LIPFENDRA (enlicitide) FDA approval crystallized: RBC Capital Markets called the label 'the cleanest in the PCSK9 class' with zero contraindications or hypersensitivity warnings, financial analysts modeled $2 billion-plus peak sales, and the CORALreef Outcomes cardiovascular trial (NCT06008756) confirmed complete enrollment at more than 14,500 participants. Novartis received FDA traditional approval today for Fabhalta (iptacopan), a first-in-class complement Factor B inhibitor that slowed eGFR decline 48% versus placebo in primary IgA nephropathy — the same indication Vera Therapeutics' Trutakna (atacicept, peptide-and-Fc fusion protein) received accelerated approval for on July 7.

Regulatory

House Select Committee on the Chinese Communist Party Response Deadline Arrives at 5:00 PM ET Today Friday July 17 for Five US Drugmakers on Records of Clinical Trials Conducted at Xinjiang-Region Hospitals and Chinese Military Medical Centers: Merck (224 China Studies Since 2005, 31 Xinjiang + 40 Military), Eli Lilly (220+ Studies Since 2003, 11 Xinjiang + 16 Military), Pfizer (6 Xinjiang + 43 Military), AbbVie (100+ Studies, 17 Xinjiang + 16 Military), Bristol-Myers Squibb (180 China Studies Since 2004, 8 Xinjiang + 17 Military Between 2015 and 2024)

The House Select Committee on the Chinese Communist Party (chaired by Rep. John Moolenaar, R-Michigan) reaches its 5:00 PM ET response deadline today Friday July 17, 2026 for five US drugmakers: Merck, Eli Lilly, Pfizer, AbbVie, and Bristol-Myers Squibb. The June 29 letters requested records on due diligence processes, data protection standards, and oversight procedures at Chinese trial sites, particularly Xinjiang-region hospitals and hospitals affiliated with China's military. Documented trial counts: Merck sponsored or collaborated on 224 clinical studies in China since 2005, including at least 31 trials involving Xinjiang-region hospitals and at least 40 trials at Chinese military medical centers. Eli Lilly sponsored or collaborated on more than 220 clinical studies in China since 2003, including at least 11 Xinjiang-region trials and at least 16 military-medical-center trials between 2016 and 2024. Pfizer had at least 6 Xinjiang-region trials and 43 military-hospital trials. AbbVie had 100-plus clinical studies in China since 2007, including at least 17 Xinjiang-region and 16 military. Bristol-Myers Squibb had approximately 180 China studies since 2004, including at least 8 Xinjiang and 17 military between 2015 and 2024. The Committee letters state there is no evidence any of the five drugmakers engaged in illegal activity or wrongdoing. Merck said patient safety and ethical integrity are foundational; Eli Lilly said it is reviewing the letter closely; AbbVie declined to comment.

#house-china-committee #john-moolenaar #merck #abbvie #eli-lilly #pfizer #bristol-myers-squibb #xinjiang #clinical-trials #national-security #biosecure-act

Industry

Merck LIPFENDRA (Enlicitide) Post-Approval Analyst Coverage: Financial Analysts Model More Than $2 Billion in Peak Annual Sales After First Few Years on the Market, RBC Capital Markets Calls the Label 'The Cleanest in the PCSK9 Class' With Zero Contraindications or Hypersensitivity Warnings (Unlike Approved Injectable Competitors Amgen Repatha, Regeneron/Sanofi Praluent, and Novartis Leqvio), and Merck Confirms the CORALreef Outcomes Cardiovascular Trial (NCT06008756) Has Completed Enrollment at More Than 14,500 Participants to Test the Cardiovascular Morbidity and Mortality Question

Analyst coverage of Merck's LIPFENDRA (enlicitide) FDA approval (Thursday July 16) crystallized Friday. Financial analysts projected LIPFENDRA can generate more than $2 billion in annual sales after a few years on the market. RBC Capital Markets described the label as 'the cleanest in the PCSK9 class,' noting zero contraindications or hypersensitivity warnings, unlike the currently approved injectable PCSK9 competitors (Amgen Repatha/evolocumab, Regeneron/Sanofi Praluent/alirocumab, and Novartis Leqvio/inclisiran). In supporting Phase 3 data, LIPFENDRA statistically outperformed other oral non-statin drugs (Nexletol/bempedoic acid and Zetia/ezetimibe) in adjunctive hypercholesterolemia populations. LIPFENDRA continues to be evaluated in the large cardiovascular outcomes trial CORALreef Outcomes (NCT06008756), which Merck confirmed has completed enrollment with more than 14,500 participants. It is not yet known whether LIPFENDRA reduces cardiovascular morbidity and mortality; the outcomes trial will address that question. Additional data on the safety profile: in CORALreef Lipids, adverse-reaction frequencies were similar between LIPFENDRA and placebo; in CORALreef HeFH the most common adverse reactions more frequent versus placebo were diarrhea (7% vs. 2%) and dizziness (9% vs. 4%), with discontinuation rates similar to placebo.

#merck #lipfendra #enlicitide #pcsk9-inhibitor #macrocyclic-peptide #rbc-capital #coralreef-outcomes #analyst-forecast #cardiovascular-outcomes #repatha #praluent #leqvio

Regulatory

FDA Grants Novartis Fabhalta (Iptacopan) Traditional Approval Today Friday July 17 as the First and Only Complement Factor B Inhibitor Approved to Slow Kidney Function Decline in Adults With Primary IgA Nephropathy at Risk of Disease Progression: Phase 3 APPLAUSE-IgAN Data Showed a 3.02 mL/min/1.73 m² Per Year Difference in eGFR Slope for a 48% Slower Decline in Patients Receiving Iptacopan Versus Placebo, Following the August 2024 Accelerated Approval for Proteinuria Reduction; The Approval Extends the IgAN Competitive Set That Vera Therapeutics Entered on July 7 With Trutakna (Atacicept-Vymj) BAFF/APRIL Peptide-and-Fc Fusion Protein Accelerated Approval

Novartis (SIX: NOVN) announced Friday July 17, 2026 that the FDA has granted traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. Fabhalta is a first-in-class complement Factor B inhibitor (small molecule); the traditional approval converts the August 2024 FDA accelerated approval (which was based on proteinuria reduction) into a full label supported by kidney-function outcomes. The Phase 3 APPLAUSE-IgAN trial showed a 3.02 mL/min/1.73 m² per year difference in estimated glomerular filtration rate (eGFR) slope in the iptacopan arm versus placebo, translating to a 48% slower kidney-function decline. The approval extends the primary IgA nephropathy competitive set that Vera Therapeutics entered on July 7, 2026 when Trutakna (atacicept-vymj), a BAFF/APRIL-targeting peptide-and-Fc fusion protein, received FDA accelerated approval based on a 45.7% versus 6.8% reduction in urine protein-to-creatinine ratio in the Phase 3 ORIGIN trial. IgA nephropathy affects approximately 130,000-150,000 Americans and is the most common primary glomerular disease worldwide; roughly 40% of patients progress to end-stage renal disease within 20 years without effective treatment.

#novartis #fabhalta #iptacopan #iga-nephropathy #complement-factor-b #applause-igan #egfr-slope #traditional-approval #vera-therapeutics #trutakna

Regulatory

FDA Pharmacy Compounding Advisory Committee Peptide Meeting Six Days Out — Written-Comment Docket FDA-2025-N-6895 Closes at 11:59 PM ET Wednesday July 22 Ahead of the July 23-24 Vote on BPC-157, KPV, TB-500, MOTS-c, DSIP/Emideltide, Semax, and Epitalon; FDA Career-Staff Briefing Documents Released June 29-30 Recommended Against Adding Any of the Seven Peptides to the 503A Bulks List, and HHS Secretary RFK Jr.'s Public Push Runs Counter to the Career-Staff Recommendation

The FDA Pharmacy Compounding Advisory Committee (PCAC) meeting on seven research peptides is six days out. The written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET Wednesday July 22, one day before the meeting opens July 23-24 at White Oak. Day 1 (July 23) covers BPC-157, KPV, TB-500, and MOTS-c. Day 2 (July 24) covers DSIP (Emideltide), Semax, and Epitalon. FDA career-staff briefing documents released June 29-30 concluded all seven peptides have insufficient evidence for 503A bulks-list eligibility, citing immunogenicity questions, heavy-metal and microbial contamination in compounding-channel samples, mislabeled contents, and thin 503A historical use. HHS Secretary Robert F. Kennedy Jr.'s public push for expanded peptide access runs counter to the career-staff recommendation, and at least seven of the eight new PCAC panelists named June 29 have documented ties to peptide-related businesses (per STAT News reporting). Comments filed by the July 9 member-review cutoff are already in the reading packet; comments filed between July 10 and July 22 will be on the record but reach members after their initial review. A 'no' vote does not re-ban anything (the seven peptides came off Category 2 April 23), but a 'yes' vote requires FDA rulemaking (typically 6-18 months) before compounding pharmacies can act on it.

#pcac #fda #docket #bpc-157 #kpv #tb-500 #mots-c #emideltide #semax #epitalon #peptide-compounding #rfk-jr